Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Clinical trial NCT01874353 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT01874353
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Platinum Sensitive BRCA Mutated Relapsed Ovarian Cancer Following Complete or Partial Response to Platinum Based Chemotherapy

Start date: 2013-09-03
Primary completion: 2016-09-19
Enrollment: 327

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.